Pharmafile Logo
Pharmafocus logo
Advanced Search

Otsuka to take over Astellas’ Cefixime business

pharmafile | June 7, 2019 | News story | Medical Communications |  APIs, Antibiotics, Astellas, Otsuka, antimicrobial, pharma 

Japanese firm Otsuka Chemical has bought Astellas Pharma’s antibiotic Cefixime.

The agreement gives Otsuka the right to sell Cefixime and supply the active pharmaceutical ingredient (API) to overseas licensees.

The move comes as part of an effort from Otsuka to strengthen their grounding in the API business.

Advertisement

Astellas’ Cefixime is a third generation cephalosporin with antibacterial activity against gram-positive and gram-negative bacteria. The antibiotic is prescribed around the world.

Otsuka said they intend to further strengthen their business through new technologies as they take advantage of key technologies.

Louis Goss

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site

Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …

The Gateway to Local Adoption Series

Latest content

Molnlycke donates risk prediction patent to SKF’s digital patent platform

November 14, 2025

Study finds at-home brain stimulation therapies reduce depression relapse rate

November 14, 2025

Smurfit Westrock unveils new clinical packaging facility at Dublin Airport

November 13, 2025

EVerZom enters research and licensing agreement with GENFIT

November 13, 2025

University of Birmingham scientists develop new MRI contrast agent

November 12, 2025